Conclusion Both ITP and NP regimens are effective for the advanced NSCLC.
结论ITP和NP方案是治疗晚期NSCLC较有效的方案。
This information warrants further investigation of subpopulations in treatment of advanced NSCLC.
这些信息使进一步调查晚期非小细胞肺癌治疗亚组成为有理由的。
Methods Clinical data of 541 female patients with advanced NSCLC were collected and followed up till death.
方法收集541例女性晚期NSCLC患者的临床资料，并随访至死亡。
Palliative surgery should be a part of multidisciplinary therapy for selective patients with advanced NSCLC.
在经过选择的晚期非小细胞肺癌患者，减状性手术应为综合治疗的一部分。
In a non-protocol setting, we now have several active agents which may be useful in the treatment of advanced NSCLC.
在临床实践中，我们现有几个药物可以用于晚期NSCLC的治疗。
Conclusion The combined regimens of NP, nc and TC are effective and well-tolerated regimens for elder advanced NSCLC.
结论NP、NC、TC联合方案是治疗老年晚期NSCLC有效且耐受性较好的方案。
The incidence of adverse thrombotic events was higher in the advanced NSCLC group than in the non-advanced NSCLC group.
目的探讨晚期非小细胞肺癌（NSCLC）患者凝血指标分布特点及与患者预后、中医证型和远期血栓性事件的相关性。
Based on what you read, how likely would you be to use IRESSA as 1st line treatment in advanced NSCLC in your patients?
根据您刚才读的内容，您对于晚期NSCLC患者使用易瑞沙作为一线治疗的意愿有多大？
Conclusion: the use of TP chemotherapy combined with thermotherapy can increase effect in the treatment of advanced NSCLC.
结论：TP方案局部热疗联合可提高单纯化疗治疗中晚期非小细胞肺癌的疗效。
Methods The expression of ERCC1, RRM1 and BRCA1 protein in 122 cases of advanced NSCLC was detected by immunohistochemical methods.
方法应用免疫组织化学方法对122例晚期NSCLC组织进行ERCC1、RRM1及BRCA1蛋白表达检测。
It is a new, effective therapy in treatment of BAI with anticancer agents and cytokines via indwelling catheter for advanced NSCLC.
由此证明，留置导管及细胞因子与BAI的有机配合，为中晚期NSCLC的治疗提供了一种新的、有效方法。
OBJECTIVE: To compare of and evaluate the efficacy and adverse reaction of NP, MVP and ICE regimens in the treatment of patients with advanced NSCLC.
目的：比较NP方案和MVP方案及ICE方案治疗晚期非小细胞肺癌(NSCLC)的近期疗效和不良反应，指导临床选择治疗方案。
Objective Retrospective analysis was conducted on the survival situation of 372 patients with advanced NSCLC, to assess the effects of various factors on survival time.
目的回顾性分析372例晚期非小细胞肺癌患者的生存现状，评估各类因素对生存期的影响。
Conclusion: Aiyishu injection could alleviate the symptoms, improve the quality of life in the advanced NSCLC patients. Aiyishu injection could reduce the toxicity of chemotherapy.
结论：艾易舒注射液能够缓解晚期非小细胞肺癌患者临床症状，改善生存质量，与化疗合用能够减轻化疗药物的毒副反应。
I would now like to focus for the remainder of our discussion on how best to convey a compelling picture for Iressa in advanced NSCLC as 1st line in EGFR mutation positive patients.
在此次访问的最后部分我想请各位阐述以下如何才能最好的传达一幅引人注目的画面，说明易瑞沙是针对EGFR突变阳性的晚期NSCLC患者的一线治疗方法。
As the current evidence shows, pemetrexed has similar efficacy to docetaxel for advanced NSCLC patients, but it has fewer side effects of neutropenia, febrile neutropenia and alopecia.
结论当前证据显示，培美曲塞与多西紫杉醇治疗晚期NSCLC的疗效相当，但可减少中性粒细胞减少、粒细胞性发热和脱发等不良反应。
Conclusions: Concurrent radiochemotherapy is a feasible, well tolerated and active scheme in the treatment of locally advanced NSCLC. The major pattern of failure is distant metastasis.
结论：同步放化疗治疗局部晚期非小细胞肺癌具有较好的疗效，不良反应可耐受，治疗失败原因主要为远处转移。
Conclusion GP programs and TP program is effective and with advanced NSCLC, there are some differences in adverse reactions, according to different individuals use different chemotherapy regimens.
结论GP方案和TP方案对晚期NSCLC疗效肯定，不良反应有一定差异，可根据不同个体选用不同的化疗方案。
Conclusion: a higher response rate is attainable in patients with advanced NSCLC treated by MMC, VDS and DDP with tolerable toxicity, especially in patients who had not been treated with chemotherapy.
结论：MMC、VDS、DDP联合化疗治疗晚期非小细胞肺癌，有效率较高，毒性可以耐受，尤其适用于初治患者。
Objective: to evaluate the clinical effect and toxicity of gemcitabine monotherapy in the treatment of elder advanced non-small cell lung cancer (NSCLC).
目的观察了解吉西他滨单药治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和毒性反应。
Objective:To compare the clinical activity, survival and toxicity of IVP and CAP for advanced non small cell cancer(NSCLC)in aged.
目的对比IVP方案与CAP方案治疗老年晚期非小细胞肺癌的临床疗效、生存期及毒副反应。
Objective to observe the efficacy and toxicity of gemcitabine plus Carboplatin in the treatment of advanced non-small-cell lung cancer (NSCLC).
目的观察吉西他滨联合伯尔定治疗晚期非小细胞肺癌的疗效及毒副作用。
Objective To evaluate the toxicity and clinical activity of navelbine(NVB) plus cisplation(DDP) and gemcitabine(GEM) plus cisplation in the treatment of advanced non-small cell lung cancer(NSCLC).
目的评价长春瑞滨（NVB）与顺铂（DDP）及吉西他滨（GEM）与顺铂联合化疗治疗晚期非小细胞癌（NSCLC）的疗效及毒副作用。
Method: 30 patients with advanced non small cell lung cancer (NSCLC) were treated by Paclitaxel combined chemotherapy, which at least each of given 2 cycles.
方法：对30例晚期非小细胞肺癌患者采用含泰素联合化疗，每例至少化疗2周期。
Objective To evaluate near therapeutic effect of advanced non small cell lung cancer (NSCLC), treated with NP regimen or EP regimen.
目的探讨NP与EP方案对晚期非小细胞肺癌的近期疗效。
Objective To support a reasonable and standard TCM treatment principle for advanced non-small-cell lung cancer (NSCLC) by exploring TCM syndrome features in NSCLC patients with factor analysis.
目的采用因子分析的方法，探讨晚期非小细胞肺癌（NSCLC）中医临床证候特征，为中医药合理规范化地参与晚期肺癌的治疗提供思路。
Gemcitabine is a new active drug in the treatment of advanced non small cell lung cancer (NSCLC).
吉西他滨是近年来治疗晚期非小细胞肺癌的有效新药。
Objective To investigate the expression of DNA repair gene family members of ERCC1, RRM1 and BRCA1 in tissues of advanced non-small cell lung cancer (NSCLC), and explore its clinical significance.
目的探讨晚期非小细胞肺癌(NSCLC)组织中DNA修复基因家族成员ERCC1、RRM1和BRCA1的表达及其临床意义。
Objective: To compare the clinic effect and the adverse effect of Delisheng injection with NP regimen in advanced non-small cell lung cancer (NSCLC).
目的：对比观察得力生注射液与NP方案治疗晚期非小细胞肺癌的临床疗效和毒副反应。
Objective: To compare the clinic effect and the adverse effect of Delisheng injection with NP regimen in advanced non-small cell lung cancer (NSCLC).
目的：对比观察得力生注射液与NP方案治疗晚期非小细胞肺癌的临床疗效和毒副反应。
应用推荐